- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05848284
Klinische veiligheid en werkzaamheid van het VDyne transkatheter tricuspidalisklepvervangingssysteem voor de behandeling van tricuspidalisregurgitatie (VISTA-US) (VISTA-US)
Klinische veiligheid en werkzaamheid van het VDyne transkatheter tricuspidalisklepvervangingssysteem voor de behandeling van tricuspidalisregurgitatie
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Vinny Podichetty
- Telefoonnummer: 763-777-5969
- E-mail: vpodichetty@vdyne.com
Studie Contact Back-up
- Naam: Jeya Satheesh
- Telefoonnummer: 952-686-8158
- E-mail: jsatheesh@vdyne.com
Studie Locaties
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Werving
- Québec-Université Laval (IUCPQ-ULaval)
-
Contact:
- Dominique Lachance Clinical Study Coordinator
- Telefoonnummer: 3055 (418) 656-8711
- E-mail: Dominique.Lachance@criucpq.ulaval.ca
-
Hoofdonderzoeker:
- Joseph Rodés, MD
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90048
- Werving
- Cedars-Sinai Medical Center
-
Hoofdonderzoeker:
- Raj Makkar
-
Contact:
- Mitch Gheorghiu
- Telefoonnummer: 3104236152
- E-mail: Mitch.Gheorghiu@cshs.org
-
-
Michigan
-
Detriot, Michigan, Verenigde Staten, 48208
- Actief, niet wervend
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Actief, niet wervend
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic - Rochester
-
Contact:
- Adam Logeman
- Telefoonnummer: 507-422-2263
- E-mail: Logeman.Adam@mayo.edu
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Werving
- Columbia University Medical Center/NYPH
-
Hoofdonderzoeker:
- Torsten Vahl, MD
-
Contact:
- Treena Williams
- Telefoonnummer: 2123423485
- E-mail: taw2112@cumc.columbia.edu
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Montefiore Medical Center
-
Contact:
- Kara Booth
- Telefoonnummer: (718) 920-6523
- E-mail: kbooth@montefiore.org
-
Hoofdonderzoeker:
- Edwin Ho, MD
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- The Christ Hospital
-
Contact:
- Belinda Frakes
- Telefoonnummer: 5135851777
- E-mail: Belinda.frakes@thechristhospital.com
-
Hoofdonderzoeker:
- Santiago Garcia
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Werving
- Oregon Health and Science Unversity
-
Hoofdonderzoeker:
- Firas Zahr, MD
-
Contact:
- Anna Garwood
- Telefoonnummer: 503-494-3472
- E-mail: garwood@ohsu.edu
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina
-
Contact:
- Natalie Drain, MHA
- Telefoonnummer: 843-876-5037
- E-mail: drain@musc.edu
-
Hoofdonderzoeker:
- Nick Amoroso, MD
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37205
- Werving
- Ascension St. Thomas
-
Hoofdonderzoeker:
- Andrew Morse, MD
-
Contact:
- Erin Beller, BSN, RN
- Telefoonnummer: 6152226997
- E-mail: erin.beller@ascension.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
- NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
- Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
- index procedure, including a diuretic.
- Heart Team determines patient is a recommended candidate for the VDyne System.
- Age >18 years at time of index procedure.
- Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.
Exclusion Criteria:
- Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs, Sponsor or Clinical Screening Committee (CSC)
- Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
- Hypersensitivity to nickel or titanium
- Left Ventricular Ejection Fraction (LVEF) <30%.
- Severe RV dysfunction.
- Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
- Sepsis including active infective endocarditis (IE) (within last 6 months).
- Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
- Severe tricuspid annular or leaflets calcification.
- Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg.
- History or rheumatic fever
- Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
- Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound).
- Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
- Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
- Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
- Significant valvular heart disease requiring intervention other than the tricuspid valve.
- Known significant intracardiac shunt (e.g. septal defect)
- Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
- Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
- Acute myocardial infarction (AMI) within 30 days.
- Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis.
- End-stage liver disease (MELD > 11 / CHILD class C).
- Bleeding requiring transfusion within prior 30 days.
- Coagulopathy or other clotting disorder that cannot be medically managed.
- Chronic immunosuppression or other condition that could impair healing response.
- Any of the following: leukopenia, chronic anemia (Hgb < 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
- Unwilling to receive blood products.
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
- Life expectancy less than 12 months due to non-cardiac comorbidities.
- Treatment is not expected to provide benefit (futile).
- Current IV Drug user (must be free drug abuse for > 1 year).
- Pregnant, lactating or planning pregnancy within next 12 months.
- Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
- Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
- Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
- Patient unable or unwilling to comply with study required testing and follow-up visits
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: VDyne System Treatment Arm
Device |
The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Tijdsspanne: Implant to 30 days post-procedure
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC). |
Implant to 30 days post-procedure
|
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Tijdsspanne: Baseline to 1 month after implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs |
Baseline to 1 month after implant
|
|
Changes in symptom status (NYHA class)
Tijdsspanne: Baseline to 1 month after implant
|
Changes in symptom status (NYHA class) |
Baseline to 1 month after implant
|
|
Changes in functional capacity (6-minute walk test)
Tijdsspanne: Baseline to 1 month after implant
|
Changes in functional capacity (6-minute walk test) |
Baseline to 1 month after implant
|
|
Changes in in quality of life (KCCQ score)
Tijdsspanne: Baseline to 1 month after implant
|
Changes in in quality of life (KCCQ score). A higher score indicates worsening quality of life outcomes |
Baseline to 1 month after implant
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).
Tijdsspanne: 30 days post-procedure to 1 year
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC). |
30 days post-procedure to 1 year
|
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs |
1 month after implant to 1 year post-implant
|
|
Changes in right ventricle as measured by core lab
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Changes in the right ventricle as measured by core lab |
1 month after implant to 1 year post-implant
|
|
Rate of heart failure hospitalization
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Rate of heart failure hospitalization |
1 month after implant to 1 year post-implant
|
|
Changes in symptom status (NYHA class)
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Changes in symptom status (NYHA class) |
1 month after implant to 1 year post-implant
|
|
Changes in functional capacity (6-minute walk test)
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Changes in functional capacity (6-minute walk test) |
1 month after implant to 1 year post-implant
|
|
Changes in in quality of life (KCCQ score).
Tijdsspanne: 1 month after implant to 1 year post-implant
|
Changes in in quality of life (KCCQ score). A higher score indicates worsening outcomes |
1 month after implant to 1 year post-implant
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TPR0037-P
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .